The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Neoadjuvant vs perioperative immunotherapy in resectable NSCLC
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, explores the evidence for neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer (NSCLC), highlighting similar survival and pathologic complete response rates. It is not yet clear which patients benefit from perioperative immunotherapy, and biomarkers or ctDNA may need to be used to identify these patients going forward. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
